TXMD

TherapeuticsMD, Inc. (TXMD) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. TherapeuticsMD, Inc. transformed in December 2022 from a commercial women's healthcare company into a pharmaceutical royalty company. The company no longer conducts research, development, or commercial operations. Its primary revenue source is royalties and milestone payments from licensees, principally Mayne Pharma LLC (U.S. rights to IMVEXXY, BIJUVA, ANNOVERA, and prenatal vitamins), Knight Therapeutics (Canada/Israel), and Theramex (International). Historical commercial operations are reported as discontinued operations.

Key Financial Metrics

Note: Revenue consists entirely of license and service revenue. The company has no debt listed on the balance sheet, though it has operating lease liabilities of $6,004 thousand.

Material Changes vs. Prior Period

• Revenue Decline: Q2 2024 revenue decreased 46.5% year-over-year to $234,000, primarily due to lower sales of licensed products by partners.
• Improved Net Loss: Net loss narrowed significantly to $1.09 million in Q2 2024 from $2.41 million in Q2 2023. This improvement is driven by reduced operating expenses and a one-time gain.
• Operating Expenses: SG&A expenses dropped 55.7% to $1.23 million due to business optimization. However, this was partially offset by a $1.261 million impairment charge related to abandoned patents and pending applications.
• Other Income: A significant one-time gain of $1.25 million was recognized in Q2 2024 from the early termination of a sublease, boosting other income to $1.395 million.
• Cash Position: Cash balances decreased from $13.7 million at the end of 2023 to $5.2 million at June 30, 2024, despite positive operating cash flow for the first half of 2024.

Outlook, Risks, and Contingencies

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next twelve months. The company may need to raise additional capital to fund operations until it becomes cash flow positive.
• Mayne Pharma Dispute: A dispute exists regarding the calculation of allowances for payer rebates and wholesale distributor fees under the 2022 Transaction Agreement. Mayne Pharma's calculation differs significantly from the company's estimate. The outcome is uncertain, and no additional liability has been accrued.
• Patent Litigation: The company is defending its IMVEXXY patents against Paragraph IV certifications from Teva Pharmaceuticals (stayed since 2021) and Sun Pharma (filed July 2024). Mayne Pharma is responsible for enforcement costs. Capitalized legal costs of $2.334 million are currently held in prepaid assets.
• Revenue Structure: Future revenue depends on Mayne Pharma achieving sales milestones ($100M, $200M, $300M) and paying minimum annual royalties of $3.0 million (inflation-adjusted) for 12 years.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $5.2 million cash balance against projected operating expenses and the timeline for potential equity financing.
• Mayne Pharma Settlement: Monitor the resolution of the net working capital dispute regarding payer rebates and distributor fees, as a material payment could be required.
• Patent Defense Status: Track the status of the Sun Pharma litigation and the stayed Teva litigation, as a loss could result in immediate expensing of capitalized legal costs and reduced royalty rates.
• Partner Sales Performance: Review sales data from Mayne Pharma, Knight, and Theramex to assess the likelihood of hitting the $100M sales milestone for the $5M payment.
• Impairment Review: Confirm if further patent impairments are likely given the company's strategy of abandoning certain pending applications.